GlassScriptPhysician profile
Eliud Irizarry Claudio
NPI 1508950122
$2,975.03
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $1,213 · 2021: $156.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $249.15 | 2019-2020 | |
| Biogen, INC. | $219.31 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $190.26 | 2019-2020 | |
| Genzyme Corporation | $185.40 | 2019-2020 | |
| Lundbeck LLC | $184.51 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $144.63 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $127.65 | 2019-2020 | |
| Eisai INC. | $115.18 | 2019-2020 | |
| Emd Serono, INC. | $112.92 | 2019 | |
| Livanova USA, INC. | $105.20 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $100.11 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $97.34 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $94.74 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $79.36 | 2019-2020 | |
| Mdd US Operations, LLC | $73.37 | 2019-2020 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $69.07 | 2019-2020 | |
| Horizon Therapeutics Plc | $67.54 | 2021 | |
| Sk Life Science, INC. | $64.24 | 2020 | |
| Allergan, INC. | $60.57 | 2019-2020 | |
| Abbvie INC. | $51.77 | 2019-2021 | |
| Csl Behring | $49.66 | 2019-2020 | |
| Greenwich Biosciences, INC. | $48.65 | 2019 | |
| Mallinckrodt Hospital Products INC. | $48.55 | 2020 | |
| Neurelis, INC. | $45.46 | 2020 | |
| Amneal Pharmaceuticals LLC | $39.18 | 2019-2020 | |
| Shire North American Group INC | $37.35 | 2019 | |
| Acadia Pharmaceuticals INC | $35.10 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.37 | 2020 | |
| Amgen INC. | $26.34 | 2019 | |
| Lilly USA, LLC | $25.38 | 2019 | |
| Saol Therapeutics INC. | $22.26 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.78 | 2019 | |
| Kyowa Kirin, INC. | $19.34 | 2020 | |
| Jazz Pharmaceuticals INC. | $18.77 | 2020 | |
| Boston Scientific Corporation | $16.39 | 2019 | |
| Promius Pharma LLC | $16.05 | 2019 | |
| Celgene Corporation | $15.41 | 2020 | |
| Pfizer INC. | $14.33 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.12 | 2020 | |
| Abbott Laboratories | $14.12 | 2019 | |
| Strongbridge US INC. | $12.15 | 2019 | |
| Ceribell, INC. | $10.95 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliud Irizarry Claudio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.